Compare CMCT & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | CMMB |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.8M |
| IPO Year | 1996 | 2023 |
| Metric | CMCT | CMMB |
|---|---|---|
| Price | $4.84 | $2.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 25.8K | ★ 63.4K |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $116,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $53.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $1.35 |
| 52 Week High | $14.41 | $3.86 |
| Indicator | CMCT | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 68.34 |
| Support Level | $2.72 | $1.45 |
| Resistance Level | $5.14 | $2.21 |
| Average True Range (ATR) | 0.60 | 0.14 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 37.10 | 78.15 |
Creative Media & Community Trust Corp is a Maryland corporation and REIT. It mainly acquires, develops, owns, and operates both multifamily properties situated in vibrant communities throughout the United States and Class A and creative office real assets in markets with similar business and employment characteristics to multifamily investments. All of its communities are located in areas that include traditional downtowns and suburban main streets, which have high barriers to entry, high population density, positive population trends, and a propensity for growth. Currently, the company consists of three types of commercial real estate properties, namely office, hotel, and multifamily.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.